2 5-DIBROMO-3-CYCLOHEXYLTHIOPHENE 97 - CAS 302912-44-3
Category:
Main Product
Product Name:
2 5-DIBROMO-3-CYCLOHEXYLTHIOPHENE 97
Catalog Number:
302912-44-3
Synonyms:
2,5-dibromo-3-cyclohexylthiophene; 2,5-Dibromo-3-cyclohexylthiophene; 302912-44-3; AC1MOBCK; C10H12Br2S; SCHEMBL197004
CAS Number:
302912-44-3
Molecular Weight:
324.079
Molecular Formula:
C10H12Br2S
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
C1CCC(CC1)C2=C(SC(=C2)Br)Br
InChI:
InChI=1S/C10H12Br2S/c11-9-6-8(10(12)13-9)7-4-2-1-3-5-7/h6-7H,1-5H2
InChIKey:
GQDHHQWPBULMEB-UHFFFAOYSA-N
Chemical Structure
CAS 302912-44-3 2 5-DIBROMO-3-CYCLOHEXYLTHIOPHENE  97

Reference Reading


1.SPACE-2: A Missed Opportunity to Compare Carotid Endarterectomy, Carotid Stenting, and Best Medical Treatment in Patients with Asymptomatic Carotid Stenoses.
Eckstein HH1, Reiff T2, Ringleb P2, Jansen O3, Mansmann U4, Hacke W5; SPACE 2 Investigators. Eur J Vasc Endovasc Surg. 2016 Apr 13. pii: S1078-5884(16)00097-6. doi: 10.1016/j.ejvs.2016.02.005. [Epub ahead of print]
BACKGROUND: Because of recent advances in best medical treatment (BMT), it is currently unclear whether any additional surgical or endovascular interventions confer additional benefit, in terms of preventing late ipsilateral carotid territory ischemic stroke in asymptomatic patients with significant carotid stenoses. The aim was to compare the stroke-preventive effects of BMT alone, with that of BMT in combination with carotid endarterectomy (CEA) or carotid artery stenting (CAS) in patients with high grade asymptomatic extracranial carotid artery stenosis.
2.Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
Abou-Alfa GK1, Puig O2, Daniele B3, Kudo M4, Merle P5, Park JW6, Ross P7, Peron JM8, Ebert O9, Chan S10, Poon TP11, Colombo M12, Okusaka T13, Ryoo BY14, Minguez B15, Tanaka T16, Ohtomo T16, Ukrainskyj S2, Boisserie F2, Rutman O2, Chen YC2, Xu C2, Shochat J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30106-4. doi: 10.1016/j.jhep.2016.04.004. [Epub ahead of print]
PURPOSE: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in HCC, interacts with CD16/ FcγRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied versus placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy.
3.Treatment With Prothrombin Complex Concentrate to Enable Emergency Lumbar Puncture in Patients Receiving Vitamin K Antagonists.
Laible M1, Beynon C2, Sander P3, Purrucker J1, Müller OJ4, Möhlenbruch M5, Ringleb PA1, Rizos T6. Ann Emerg Med. 2016 Apr 14. pii: S0196-0644(16)00158-X. doi: 10.1016/j.annemergmed.2016.03.003. [Epub ahead of print]
STUDY OBJECTIVE: Lumbar punctures are frequently necessary in neurologic emergencies, but effective oral anticoagulation with vitamin K antagonists represents a contraindication. We report the effectiveness of prothrombin complex concentrates to reverse vitamin K antagonist to enable emergency lumbar punctures, as well as evaluate lumbar puncture- and prothrombin complex concentrates-related complications.
4.Statistical modelling of the rheological and mucoadhesive properties of aqueous poly(methylvinylether-co-maleic acid) networks: Redefining biomedical applications and the relationship between viscoelasticity and mucoadhesion.
Jones DS1, Laverty TP2, Morris C2, Andrews GP2. Colloids Surf B Biointerfaces. 2016 Mar 4;144:125-134. doi: 10.1016/j.colsurfb.2016.03.008. [Epub ahead of print]
Poly(methylvinylether-co-maleic acid) (PMVE/MA) is commonly used as a component of pharmaceutical platforms, principally to enhance interactions with biological substrates (mucoadhesion). However, the limited knowledge on the rheological properties of this polymer and their relationships with mucoadhesion has negated the biomedical use of this polymer as a mono-component platform. This study presents a comprehensive study of the rheological properties of aqueous PMVE/MA platforms and defines their relationships with mucoadhesion using multiple regression analysis. Using dilute solution viscometry the intrinsic viscosities of un-neutralised PMVE/MA and PMVE/MA neutralised using NaOH or TEA were 22.32±0.89dLg-1, 274.80±1.94dLg-1 and 416.49±2.21dLg-1 illustrating greater polymer chain expansion following neutralisation using Triethylamine (TEA). PMVE/MA platforms exhibited shear-thinning properties. Increasing polymer concentration increased the consistencies, zero shear rate (ZSR) viscosities (determined from flow rheometry), storage and loss moduli, dynamic viscosities (defined using oscillatory analysis) and mucoadhesive properties, yet decreased the loss tangents of the neutralised polymer platforms.